603392 万泰生物
已收盘 03-09 15:00:00
资讯
新帖
简况
每周股票复盘：万泰生物（603392）2025年预亏最高6.6亿
证券之星 · 02-01
每周股票复盘：万泰生物（603392）2025年预亏最高6.6亿
万泰生物最新公告：预计2025年净亏损3.3亿元-4.1亿元同比转亏
证券之星 · 01-29
万泰生物最新公告：预计2025年净亏损3.3亿元-4.1亿元同比转亏
万泰生物（603392）披露二价HPV疫苗通过WHO PQ周期性复核公告，1月26日股价上涨5.87%
证券之星 · 01-26
万泰生物（603392）披露二价HPV疫苗通过WHO PQ周期性复核公告，1月26日股价上涨5.87%
1月26日万泰生物涨5.87%，嘉实中证疫苗与生物技术ETF基金重仓该股
证券之星 · 01-26
1月26日万泰生物涨5.87%，嘉实中证疫苗与生物技术ETF基金重仓该股
每周股票复盘：万泰生物（603392）拟用45亿自有资金现金管理
证券之星 · 01-18
每周股票复盘：万泰生物（603392）拟用45亿自有资金现金管理
万泰生物全资子公司万泰凯瑞完成工商变更，迁址并扩大经营范围
中金财经 · 01-17
万泰生物全资子公司万泰凯瑞完成工商变更，迁址并扩大经营范围
万泰生物入选2025“未来力量”医疗健康先锋榜 以创新引领筛防一体化解决方案
证券之星 · 01-07
万泰生物入选2025“未来力量”医疗健康先锋榜 以创新引领筛防一体化解决方案
万泰生物(603392.SH)：HIV抗体口腔黏膜渗出液自我检测试剂取得医疗器械注册证
智通财经 · 2025-12-25
万泰生物(603392.SH)：HIV抗体口腔黏膜渗出液自我检测试剂取得医疗器械注册证
万泰生物(603392.SH)：重组三价轮状病毒亚单位疫苗(大肠埃希菌)临床试验申请获得受理
智通财经 · 2025-12-25
万泰生物(603392.SH)：重组三价轮状病毒亚单位疫苗(大肠埃希菌)临床试验申请获得受理
万泰生物(603392.SH)子公司参与国家免疫规划疫苗集中采购项目入围
智通财经 · 2025-12-22
万泰生物(603392.SH)子公司参与国家免疫规划疫苗集中采购项目入围
万泰生物(603392.SH)：重组呼吸道合胞病毒疫苗(CHO细胞)临床试验申请获受理
智通财经 · 2025-12-17
万泰生物(603392.SH)：重组呼吸道合胞病毒疫苗(CHO细胞)临床试验申请获受理
万泰生物（603392）披露实施回购股份注销暨股份变动的公告，12月16日股价下跌0.63%
证券之星 · 2025-12-16
万泰生物（603392）披露实施回购股份注销暨股份变动的公告，12月16日股价下跌0.63%
万泰生物：公司九价HPV疫苗正常生产和批签发
证券日报 · 2025-12-15
万泰生物：公司九价HPV疫苗正常生产和批签发
万泰生物：公司二价HPV疫苗已在柬埔寨、泰国、缅甸、印度尼西亚等多个东南亚国家获得市场准入
每日经济新闻 · 2025-12-15
万泰生物：公司二价HPV疫苗已在柬埔寨、泰国、缅甸、印度尼西亚等多个东南亚国家获得市场准入
万泰生物最新公告：九价宫颈癌疫苗二期扩产建设项目延期至2026年12月
证券之星 · 2025-12-12
万泰生物最新公告：九价宫颈癌疫苗二期扩产建设项目延期至2026年12月
万泰争锋默沙东：HPV疫苗“最甜”的市场已经没了 | 海斌访谈
第一财经 · 2025-12-11
万泰争锋默沙东：HPV疫苗“最甜”的市场已经没了 | 海斌访谈
万泰生物（603392）披露取消监事会并修订公司章程议案获股东会通过，11月28日股价下跌2.18%
证券之星 · 2025-11-28
万泰生物（603392）披露取消监事会并修订公司章程议案获股东会通过，11月28日股价下跌2.18%
每周股票复盘：万泰生物（603392）拟取消监事会并修订多项制度
证券之星 · 2025-11-23
每周股票复盘：万泰生物（603392）拟取消监事会并修订多项制度
11月20日万泰生物现2920.56万元大宗交易
证券之星 · 2025-11-20
11月20日万泰生物现2920.56万元大宗交易
每周股票复盘：万泰生物（603392）拟取消监事会并修订公司章程
证券之星 · 2025-11-16
每周股票复盘：万泰生物（603392）拟取消监事会并修订公司章程
暂无数据
公司概况
公司名称：
北京万泰生物药业股份有限公司
所属行业：
医药制造业
上市日期：
2020-04-29
主营业务：
北京万泰生物药业股份有限公司的主营业务是诊断试剂、疫苗以及医疗器械的研发、生产和销售。公司的主要产品是体外诊断试剂、诊断仪器、重组戊型肝炎疫苗、二价HPV疫苗、鼻喷流感病毒载体新冠肺炎疫苗、九价HPV疫苗。
发行价格：
8.75
{"stockData":{"symbol":"603392","market":"SH","secType":"STK","nameCN":"万泰生物","latestPrice":39.31,"timestamp":1773039600000,"preClose":39.2,"halted":0,"volume":3066325,"delay":0,"changeRate":0.0028,"floatShares":1264000000,"shares":1264000000,"eps":-0.2641,"marketStatus":"已收盘","change":0.11,"latestTime":"03-09 15:00:00","open":38.75,"high":39.55,"low":38.59,"amount":120000000,"amplitude":0.0245,"askPrice":39.32,"askSize":90,"bidPrice":39.31,"bidSize":74,"shortable":0,"etf":0,"ttmEps":-0.2641,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773106200000},"marketStatusCode":5,"adr":0,"adjPreClose":39.2,"symbolType":"stock","openAndCloseTimeList":[[1773019800000,1773027000000],[1773032400000,1773039600000]],"highLimit":43.12,"lowLimit":35.28,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1264392804,"isCdr":false,"pbRate":4.11,"roa":"--","roe":"--","epsLYR":0.08,"committee":0.271028,"marketValue":49703000000,"turnoverRate":0.0024,"status":0,"floatMarketCap":49703000000},"requestUrl":"/m/hq/s/603392/tweets","defaultTab":"tweets","newsList":[{"id":"2608813077","title":"每周股票复盘：万泰生物（603392）2025年预亏最高6.6亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2608813077","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608813077?lang=zh_cn&edition=full","pubTime":"2026-02-01 02:15","pubTimestamp":1769883314,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘，万泰生物报收于42.05元，较上周的44.3元下跌5.08%。本周，万泰生物1月26日盘中最高价报46.98元。本周关注点来自业绩披露要点：万泰生物预计2025年扣非净利润亏损5.3亿元至6.6亿元。业绩披露要点万泰生物发布业绩预告，预计2025年全年归属净利润亏损3.3亿元至4.1亿元，扣非后净利润亏损5.3亿元至6.6亿元，较上年同期由盈转亏。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020100000597.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","LU1981816686.USD","603392","BK1200","09633","BK1589"],"gpt_icon":0},{"id":"2607707676","title":"万泰生物最新公告：预计2025年净亏损3.3亿元-4.1亿元同比转亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2607707676","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607707676?lang=zh_cn&edition=full","pubTime":"2026-01-29 17:32","pubTimestamp":1769679149,"startTime":"0","endTime":"0","summary":"万泰生物(603392.SH)公告称，预计2025年归属于上市公司股东的净利润为-4.10亿元至-3.30亿元，上年同期盈利1.06亿元，同比转亏。主要因二价HPV疫苗受集采降价、消费需求不足等影响，出现近效期无法销售及库存减值，预计影响净利润约5亿–6亿元；九价HPV疫苗虽已上市并加速准入，但报告期内利润贡献尚未充分体现；诊断板块亦受集采降价及医保政策影响，收入利润同比下滑。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900029355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["603392","BK1200","LU1981816686.USD","09633","BK0239","BK1589"],"gpt_icon":0},{"id":"2606246949","title":"万泰生物（603392）披露二价HPV疫苗通过WHO PQ周期性复核公告，1月26日股价上涨5.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606246949","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606246949?lang=zh_cn&edition=full","pubTime":"2026-01-26 22:14","pubTimestamp":1769436895,"startTime":"0","endTime":"0","summary":"截至2026年1月26日收盘，万泰生物报收于46.9元，较前一交易日上涨5.87%，最新总市值为593亿元。该股当日开盘44.3元，最高46.98元，最低44.3元，成交额达6.43亿元，换手率为1.11%。万泰生物近日发布关于二价HPV疫苗通过WHO PQ周期性复核的公告。公告显示，公司全资子公司厦门万泰沧海生物技术有限公司自主研发的二价HPV疫苗近日通过世界卫生组织PQ周期性复核，此前该疫苗已于2021年通过WHO PQ认证。此次通过复核有助于进一步开拓国际市场。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600035489.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1981816686.USD","BK0239","09633","603392","BK1589","BK1200","159646"],"gpt_icon":0},{"id":"2606750292","title":"1月26日万泰生物涨5.87%，嘉实中证疫苗与生物技术ETF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2606750292","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606750292?lang=zh_cn&edition=full","pubTime":"2026-01-26 15:36","pubTimestamp":1769413015,"startTime":"0","endTime":"0","summary":"证券之星消息，1月26日万泰生物涨5.87%，收盘报46.9元，换手率1.11%，成交量13.99万手，成交额6.43亿元。重仓万泰生物的公募基金请见下表：根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共6家，其中持有数量最多的公募基金为嘉实基金的嘉实中证疫苗与生物技术ETF。嘉实中证疫苗与生物技术ETF目前规模为2.28亿元，最新净值0.7193，较上一交易日上涨1.77%，近一年上涨13.79%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600014796.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1200","603392","BK1589","09633","BK0239","159646","LU1981816686.USD"],"gpt_icon":0},{"id":"2604923798","title":"每周股票复盘：万泰生物（603392）拟用45亿自有资金现金管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2604923798","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604923798?lang=zh_cn&edition=full","pubTime":"2026-01-18 03:14","pubTimestamp":1768677249,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，万泰生物报收于45.08元，较上周的46.78元下跌3.63%。本周关注点公司公告汇总：万泰生物拟使用不超过45亿元闲置自有资金进行现金管理。万泰生物关于使用部分闲置自有资金进行现金管理的公告指出，该事项经董事会审议通过后生效，无需提交股东大会审议，由总经理在额度内签署相关文件，财务部组织实施。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000792.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","09633","LU1981816686.USD","603392","BK1589","BK1200"],"gpt_icon":0},{"id":"2604910761","title":"万泰生物全资子公司万泰凯瑞完成工商变更，迁址并扩大经营范围","url":"https://stock-news.laohu8.com/highlight/detail?id=2604910761","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604910761?lang=zh_cn&edition=full","pubTime":"2026-01-17 09:37","pubTimestamp":1768613822,"startTime":"0","endTime":"0","summary":"中访网数据 北京万泰生物药业股份有限公司于2026年1月17日发布公告，其全资子公司厦门万泰凯瑞生物技术有限公司已完成工商变更登记并换发新营业执照。此次变更旨在适应子公司经营发展需要，优化其业务布局与运营地址，可能为进一步拓展市场和服务能力奠定基础。万泰凯瑞注册资本为5亿元人民币，此次变更不会导致公司合并报表范围发生变化。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260117/31950321.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","BK1200","LU1981816686.USD","09633","BK1589","603392"],"gpt_icon":0},{"id":"2601980809","title":"万泰生物入选2025“未来力量”医疗健康先锋榜 以创新引领筛防一体化解决方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2601980809","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601980809?lang=zh_cn&edition=full","pubTime":"2026-01-07 20:47","pubTimestamp":1767790046,"startTime":"0","endTime":"0","summary":"近日，证券之星发布2025年“未来力量”领军企业榜单，万泰生物凭借在疫苗与体外诊断领域的原创技术突破与全球化健康实践，成功入选“医疗健康先锋榜”，成为以筛防一体化解决方案守护人类健康的标杆企业。未来，万泰生物将持续深化技术创新，完善疫苗与体外诊断产品矩阵，推动筛防一体化解决方案在全球范围内的深度应用。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026010700036716.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09633","BK1200","LU1981816686.USD","159760","BK1589","603392","BK0239"],"gpt_icon":0},{"id":"2594380882","title":"万泰生物(603392.SH)：HIV抗体口腔黏膜渗出液自我检测试剂取得医疗器械注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2594380882","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594380882?lang=zh_cn&edition=full","pubTime":"2025-12-25 16:07","pubTimestamp":1766650058,"startTime":"0","endTime":"0","summary":"智通财经APP讯，万泰生物 发布公告，近日，公司自主研发的人类免疫缺陷病毒抗体口腔黏膜渗出液检测试剂盒取得国家药品监督管理局颁发的《中华人民共和国医疗器械注册证》。标志着公司在艾滋病自我检测领域的技术领先地位和创新能力再次得到国家权威认可。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385819.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159883","BK1583","BK1574","09633","BK1222","BK1100","LU1981816686.USD","09997","BK0239","BK1589","603392","09996","BK1200"],"gpt_icon":0},{"id":"2594387092","title":"万泰生物(603392.SH)：重组三价轮状病毒亚单位疫苗(大肠埃希菌)临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2594387092","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594387092?lang=zh_cn&edition=full","pubTime":"2025-12-25 16:05","pubTimestamp":1766649935,"startTime":"0","endTime":"0","summary":"智通财经APP讯，万泰生物(603392.SH)发布公告，近日，公司全资子公司厦门万泰沧海生物技术有限公司收到国家药品监督管理局行政许可文书《受理通知书》，公司申报的“重组三价轮状病毒亚单位疫苗(大肠埃希菌)”临床试验申请已获得受理。此次重组三价轮状病毒亚单位疫苗(大肠埃希菌)临床试验申请的受理，是公司创新疫苗研发过程中的重要一步，标志着公司基于大肠埃希菌自主技术平台的重组蛋白疫苗研发战略又取得关键进展，若该产品研发未来成功上市，将有利于丰富公司产品布局，进一步提高公司市场竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385816.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1589","09633","603392","LU1981816686.USD","BK1200","159646","BK0239"],"gpt_icon":0},{"id":"2593107692","title":"万泰生物(603392.SH)子公司参与国家免疫规划疫苗集中采购项目入围","url":"https://stock-news.laohu8.com/highlight/detail?id=2593107692","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593107692?lang=zh_cn&edition=full","pubTime":"2025-12-22 15:59","pubTimestamp":1766390397,"startTime":"0","endTime":"0","summary":"智通财经APP讯，万泰生物(603392.SH)发布公告，近日，公司全资子公司厦门万泰沧海生物技术有限公司参加了2025年国家免疫规划疫苗集中采购项目—双价人乳头瘤病毒疫苗采购项目的投标工作，公司双价人乳头瘤病毒疫苗(大肠埃希菌)入围。本次集中采购是中国疾病预防控制中心组织的国家免疫规划疫苗集中采购项目，若公司后续签订采购合同并组织生产与供应，将有利于扩大入围产品的销售规模，提高市场占有率，促进公司入围产品国内市场的开拓，提升公司的品牌影响力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384363.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["603392","09633","LU1981816686.USD","159646","BK0239","BK1589","BK1200"],"gpt_icon":0},{"id":"2592960398","title":"万泰生物(603392.SH)：重组呼吸道合胞病毒疫苗(CHO细胞)临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2592960398","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592960398?lang=zh_cn&edition=full","pubTime":"2025-12-17 16:22","pubTimestamp":1765959742,"startTime":"0","endTime":"0","summary":"智通财经APP讯，万泰生物(603392.SH)公告，公司全资子公司厦门万泰沧海生物技术有限公司收到国家药品监督管理局(简称“国家药监局”)行政许可文书《受理通知书》，公司申报的“重组呼吸道合胞病毒疫苗(CHO细胞)”临床试验申请已获得受理。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382552.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159646","09633","LU1981816686.USD","BK0239","BK1589","603392","BK1200"],"gpt_icon":0},{"id":"2591400980","title":"万泰生物（603392）披露实施回购股份注销暨股份变动的公告，12月16日股价下跌0.63%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591400980","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591400980?lang=zh_cn&edition=full","pubTime":"2025-12-16 22:14","pubTimestamp":1765894490,"startTime":"0","endTime":"0","summary":"截至2025年12月16日收盘，万泰生物报收于46.03元，较前一交易日下跌0.63%，最新总市值为582.34亿元。该股当日开盘46.2元，最高46.41元，最低45.72元，成交额达9732.69万元，换手率为0.17%。公司近日发布公告称，北京万泰生物药业股份有限公司决定将回购专用证券账户中已回购但尚未使用的729,970股股份注销，股份注销日为2025年12月17日。本次注销完成后，公司总股本将由1,265,122,774股减少至1,264,392,804股。本次注销不会对公司财务、经营、控制权及上市地位产生重大影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121600040680.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","09633","LU1981816686.USD","603392","BK1589","BK1200"],"gpt_icon":0},{"id":"2591564223","title":"万泰生物：公司九价HPV疫苗正常生产和批签发","url":"https://stock-news.laohu8.com/highlight/detail?id=2591564223","media":"证券日报 ","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591564223?lang=zh_cn&edition=full","pubTime":"2025-12-15 22:08","pubTimestamp":1765807680,"startTime":"0","endTime":"0","summary":"郑重声明：东方财富发布此内容旨在传播更多信息，与本站立场无关，不构成投资建议。据此操作，风险自担。 \n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-15/doc-inhawxxz3921195.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-15/doc-inhawxxz3921195.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09633","BK1200","LU1981816686.USD","159646","BK0239","BK1589","603392"],"gpt_icon":0},{"id":"2591061782","title":"万泰生物：公司二价HPV疫苗已在柬埔寨、泰国、缅甸、印度尼西亚等多个东南亚国家获得市场准入","url":"https://stock-news.laohu8.com/highlight/detail?id=2591061782","media":"每日经济新闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591061782?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:41","pubTimestamp":1765791660,"startTime":"0","endTime":"0","summary":"每经AI快讯，有投资者在投资者互动平台提问：公司管理层有计划在东南亚推广宫颈疫苗吗？万泰生物（603392.SH）12月15日在投资者互动平台表示，公司二价HPV疫苗已在柬埔寨、泰国、缅甸、印度尼西亚等多个东南亚国家获得市场准入。九价HPV疫苗将依托公司二价HPV疫苗已取得的国际化成果，构建更广阔的全球化网络，持续支持全球消除宫颈癌战略。（文章来源：每日经济新闻）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-15/doc-inhawpkc2319445.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2025-12-15/doc-inhawpkc2319445.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["603392","159646","LU1981816686.USD","BK0239","BK1589","BK1200","09633"],"gpt_icon":0},{"id":"2590577130","title":"万泰生物最新公告：九价宫颈癌疫苗二期扩产建设项目延期至2026年12月","url":"https://stock-news.laohu8.com/highlight/detail?id=2590577130","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590577130?lang=zh_cn&edition=full","pubTime":"2025-12-12 18:00","pubTimestamp":1765533630,"startTime":"0","endTime":"0","summary":"万泰生物(603392.SH)公告称，公司于2025年12月12日召开董事会，审议通过将“九价宫颈癌疫苗二期扩产建设项目”在实施主体、实施地点及投资规模不发生变更的情况下进行延期，预定可使用状态日期从2025年12月延期至2026年12月。该议案不涉及募集资金用途变更，无需提交股东会审议。公司表示，此次延期是出于确保项目建设质量和项目效益的考虑，不会对公司的正常生产经营产生不利影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121200029302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1589","BK1200","09633","LU1981816686.USD","603392","159646","BK0239"],"gpt_icon":0},{"id":"2590512273","title":"万泰争锋默沙东：HPV疫苗“最甜”的市场已经没了 | 海斌访谈","url":"https://stock-news.laohu8.com/highlight/detail?id=2590512273","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590512273?lang=zh_cn&edition=full","pubTime":"2025-12-11 23:05","pubTimestamp":1765465502,"startTime":"0","endTime":"0","summary":"本周，万泰生物九价HPV疫苗在上海开打。万泰生物与默沙东在九价HPV疫苗领域竞争的序幕已经拉开。HPV疫苗对预防宫颈癌等疾病，挽救数以万计的生命具有重大意义。目前在中国推出九价疫苗的企业只有这两家。此前，默沙东已经独占这个市场七年时间，拿走了利润最丰厚的那部分市场。现在，默沙东的代理商智飞生物已经累积了太多的库存。万泰生物以更低售价撬动价格敏感型市场。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512113589247771.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512113589247771.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["SG9999001440.SGD","LU2112291526.USD","LU0965508806.USD","LU1066051498.USD","IE00BFTCPJ56.SGD","BK4550","LU0106261372.USD","LU1585245621.USD","LU1989772923.USD","LU1699723380.USD","LU2324357040.USD","SG9999001176.SGD","LU0122379950.USD","LU1066051225.USD","LU0058720904.USD","LU1917777945.USD","BK4007","BK4585","LU0965509010.AUD","BK4559","SG9999015358.SGD","LU1934455863.HKD","SG9999013999.USD","IE00B2B36J28.USD","LU1201861249.SGD","IE00BBT3K403.USD","LU0203347892.USD","IE0002141913.USD","LU0965509283.SGD","LU2023250504.SGD","LU2089984988.USD","SGXZ57979304.SGD","LU1069347547.HKD","LU0980610538.SGD","LU1571399168.USD","LU0985320562.USD","IE000M9KFDE8.USD","SG9999015341.SGD","LU1023059063.AUD","LU2125154778.USD","LU0861579265.USD","LU1934455194.USD","LU0130517989.USD","LU0006306889.USD","LU0648001328.SGD","LU1037948541.HKD","IE0009355771.USD","LU1093756325.SGD","SG9999014567.USD","SG9999014542.SGD","BK4534","LU0320765646.SGD","LU2106854487.HKD","LU0130102774.USD","LU2361044949.HKD","LU1989771016.USD","IE00BLSP4452.SGD","LU1037948897.HKD","BK4516","LU0211331839.USD","SG9999002224.SGD","LU1941712264.USD","SG9999014559.SGD","LU0289739699.SGD","LU2360032135.SGD","LU1116320737.USD","IE00B4R5TH58.HKD","LU0265550946.USD","LU2468319806.SGD","LU1974910355.USD","LU0265550359.USD","SG9999014575.USD","LU0098860793.USD","LU0070302665.USD","LU0266013472.USD","LU1093756168.USD","LU2361044865.SGD","LU1983299246.USD","SG9999001176.USD","IE00B1BXHZ80.USD","LU1066051811.HKD","SG9999002232.USD","LU0234572021.USD","BK4533","LU0208291251.USD","LU0238689110.USD","LU0203345920.USD","LU1291159041.SGD","LU2361045086.USD","LU0320765489.SGD","LU1162221912.USD","IE00BLSP4239.USD","LU0965509101.SGD","LU1929549753.HKD","LU1066053197.SGD","LU2125154935.USD","LU1934455277.USD","IE00BJJMRZ35.SGD","LU2461242641.AUD","LU1057294990.SGD","LU1989772840.SGD","LU2023250843.SGD","LU0477156953.USD","LU1035773651.USD","MRK","BK4588","LU1430594728.SGD","IE00BN8TJ469.HKD","LU1061106388.HKD","IE00BJT1NW94.SGD","603392","LU1941712348.USD","LU1116320901.HKD","IE00BSNM7G36.USD"],"gpt_icon":0},{"id":"2586738435","title":"万泰生物（603392）披露取消监事会并修订公司章程议案获股东会通过，11月28日股价下跌2.18%","url":"https://stock-news.laohu8.com/highlight/detail?id=2586738435","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586738435?lang=zh_cn&edition=full","pubTime":"2025-11-28 22:14","pubTimestamp":1764339272,"startTime":"0","endTime":"0","summary":"截至2025年11月28日收盘，万泰生物报收于48.02元，较前一交易日下跌2.18%，最新总市值为607.51亿元。该股当日开盘49.19元，最高49.21元，最低47.96元，成交额达2.78亿元，换手率为0.46%。所有议案均获通过，无否决议案。表决结果合法有效，律师出具了见证意见。出席股东代表有表决权股份总数占公司总股本的78.6148%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112800039722.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09633","BK1200","603392","BK1589","BK0239","LU1981816686.USD"],"gpt_icon":0},{"id":"2585103680","title":"每周股票复盘：万泰生物（603392）拟取消监事会并修订多项制度","url":"https://stock-news.laohu8.com/highlight/detail?id=2585103680","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585103680?lang=zh_cn&edition=full","pubTime":"2025-11-23 02:24","pubTimestamp":1763835852,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，万泰生物报收于51.68元，较上周的54.89元下跌5.85%。本周，万泰生物11月17日盘中最高价报55.08元。11月21日盘中最低价报51.4元，股价触及近一年最低点。万泰生物当前最新总市值653.82亿元，在生物制品板块市值排名1/51，在两市A股市值排名251/5167。本周关注点来自交易信息汇总：11月20日万泰生物发生2920.56万元大宗交易。来自公司公告汇总：万泰生物拟取消监事会，由审计委员会行使监事会职权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000511.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1589","BK1200","LU1981816686.USD","603392","BK0239","09633"],"gpt_icon":0},{"id":"2584187814","title":"11月20日万泰生物现2920.56万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2584187814","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584187814?lang=zh_cn&edition=full","pubTime":"2025-11-20 17:49","pubTimestamp":1763632152,"startTime":"0","endTime":"0","summary":"证券之星消息，11月20日万泰生物发生大宗交易，交易数据如下：近三个月该股共发生3笔大宗交易，合计成交5160.0手，溢价成交3笔。该股近期无解禁股上市。截至2025年11月20日收盘，万泰生物(603392)报收于53.37元，下跌0.52%，换手率0.15%，成交量1.86万手，成交额9982.48万元。该股最近90天内无机构评级。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112000027039.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1200","603392","BK1589","09633","BK0239","LU1981816686.USD"],"gpt_icon":0},{"id":"2583651665","title":"每周股票复盘：万泰生物（603392）拟取消监事会并修订公司章程","url":"https://stock-news.laohu8.com/highlight/detail?id=2583651665","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583651665?lang=zh_cn&edition=full","pubTime":"2025-11-16 03:29","pubTimestamp":1763234951,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，万泰生物报收于54.89元，较上周的55.11元下跌0.4%。本周关注点公司公告汇总：万泰生物拟取消监事会，其职能由董事会审计委员会行使。公司公告汇总北京万泰生物药业股份有限公司于2025年11月12日召开第六届董事会第十二次会议和第六届监事会第十二次会议，审议通过《关于取消监事会并修订<公司章程>的议案》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600000838.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1589","LU1981816686.USD","BK0239","09633","BK1200","603392"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1773063264967,"stockEarnings":[{"period":"1week","weight":-0.0437},{"period":"1month","weight":-0.0658},{"period":"3month","weight":-0.1604},{"period":"6month","weight":-0.3156},{"period":"1year","weight":-0.4203},{"period":"ytd","weight":-0.1277}],"compareEarnings":[{"period":"1week","weight":-0.0093},{"period":"1month","weight":0.0054},{"period":"3month","weight":0.0567},{"period":"6month","weight":0.0818},{"period":"1year","weight":0.2198},{"period":"ytd","weight":0.0391}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京万泰生物药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"41996人(较上一季度增加9.41%)","perCapita":"30107股","listingDate":"2020-04-29","address":"北京市昌平区科学园路31号","registeredCapital":"126439万元","survey":" 北京万泰生物药业股份有限公司的主营业务是诊断试剂、疫苗以及医疗器械的研发、生产和销售。公司的主要产品是体外诊断试剂、诊断仪器、重组戊型肝炎疫苗、二价HPV疫苗、鼻喷流感病毒载体新冠肺炎疫苗、九价HPV疫苗。","listedPrice":8.75},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"万泰生物(603392)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供万泰生物(603392)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"万泰生物,603392,万泰生物股票,万泰生物股票老虎,万泰生物股票老虎国际,万泰生物行情,万泰生物股票行情,万泰生物股价,万泰生物股市,万泰生物股票价格,万泰生物股票交易,万泰生物股票购买,万泰生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"万泰生物(603392)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供万泰生物(603392)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}